{"entity":{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","aka":["Nippon Kayaku Co., Ltd.","日本化薬"],"tldr":"Nippon Kayaku is a Japanese chemicals and pharmaceuticals group whose medicines business specialises in cancer: generic chemotherapy, supportive care products and biosimilars of antibodies such as trastuzumab for the Japanese market.","summary":"Nippon Kayaku, listed in Tokyo, is a diversified chemicals company whose pharmaceutical division concentrates on oncology in Japan, supplying generic cytotoxic drugs, supportive care medicines and biosimilar antibodies including a trastuzumab biosimilar, and running the domestic phase 3 trials that biosimilar approval in Japan requires. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.nipponkayaku.co.jp/english/"},{"label":"ClinicalTrials.gov: trials led by Nippon Kayaku","url":"https://clinicaltrials.gov/search?lead=Nippon%20Kayaku"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nippon_Kayaku"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.nipponkayaku.co.jp/english/","stage":"public","investors":[],"funding":[]},"route":"/companies/nippon-kayaku/","neighbours":{"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}]}}